CN1541226A - CD44v6特异性的抗体 - Google Patents

CD44v6特异性的抗体 Download PDF

Info

Publication number
CN1541226A
CN1541226A CNA028101561A CN02810156A CN1541226A CN 1541226 A CN1541226 A CN 1541226A CN A028101561 A CNA028101561 A CN A028101561A CN 02810156 A CN02810156 A CN 02810156A CN 1541226 A CN1541226 A CN 1541226A
Authority
CN
China
Prior art keywords
antibody
seq
acid sequence
variant
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028101561A
Other languages
English (en)
Chinese (zh)
Inventor
I
冈瑟·阿道夫
埃林伯格·奥斯特曼
埃里克·帕特泽尔特
马利斯·斯普罗尔
���ġ����
卡尔-海因茨·海德
J
约翰·J·米格利塔
��Ŧ˹��A��M��S�����Ƹ�
奥古斯蒂纽斯·A·M·S·范唐根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of CN1541226A publication Critical patent/CN1541226A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CNA028101561A 2001-05-18 2002-05-17 CD44v6特异性的抗体 Pending CN1541226A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
EP01112237.1 2001-05-18
US32514701P 2001-09-26 2001-09-26
US60/325,147 2001-09-26

Publications (1)

Publication Number Publication Date
CN1541226A true CN1541226A (zh) 2004-10-27

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028101561A Pending CN1541226A (zh) 2001-05-18 2002-05-17 CD44v6特异性的抗体

Country Status (18)

Country Link
EP (1) EP1397387A1 (enExample)
JP (1) JP2005504517A (enExample)
CN (1) CN1541226A (enExample)
AR (1) AR036154A1 (enExample)
BR (1) BR0210905A (enExample)
CA (1) CA2443437A1 (enExample)
CZ (1) CZ20033476A3 (enExample)
EA (1) EA200301169A1 (enExample)
EC (1) ECSP034838A (enExample)
EE (1) EE200300569A (enExample)
HU (1) HUP0400030A3 (enExample)
MX (1) MXPA03010523A (enExample)
PE (1) PE20021098A1 (enExample)
PL (1) PL365735A1 (enExample)
SK (1) SK15592003A3 (enExample)
WO (1) WO2002094879A1 (enExample)
YU (1) YU91403A (enExample)
ZA (1) ZA200307365B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102337298A (zh) * 2011-08-19 2012-02-01 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
CN105770891A (zh) * 2007-06-13 2016-07-20 津莫吉尼蒂克斯公司 TACI-Ig 融合蛋白如ATACICEPT 用于制备治疗红斑狼疮的药物的用途
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
AU2011212485B2 (en) 2010-02-04 2014-04-17 University Of Miami A monoclonal antibody to CD44 for use in the treatment of head and neck squamous cell carcinoma
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
JP2023516080A (ja) * 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
US20250326855A1 (en) * 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
WO1994012631A1 (en) * 1992-11-20 1994-06-09 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105770891A (zh) * 2007-06-13 2016-07-20 津莫吉尼蒂克斯公司 TACI-Ig 融合蛋白如ATACICEPT 用于制备治疗红斑狼疮的药物的用途
CN102337298A (zh) * 2011-08-19 2012-02-01 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用

Also Published As

Publication number Publication date
EA200301169A1 (ru) 2004-06-24
PE20021098A1 (es) 2003-02-11
EE200300569A (et) 2004-04-15
CZ20033476A3 (cs) 2004-05-12
YU91403A (sh) 2006-05-25
AR036154A1 (es) 2004-08-18
EP1397387A1 (en) 2004-03-17
WO2002094879A1 (en) 2002-11-28
MXPA03010523A (es) 2004-07-01
ECSP034838A (es) 2003-12-24
ZA200307365B (en) 2004-05-10
CA2443437A1 (en) 2002-11-28
HUP0400030A3 (en) 2006-02-28
PL365735A1 (en) 2005-01-10
BR0210905A (pt) 2004-06-08
HUP0400030A2 (hu) 2004-04-28
SK15592003A3 (sk) 2004-06-08
JP2005504517A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
CN1541226A (zh) CD44v6特异性的抗体
US12319741B2 (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
AU2025204314A1 (en) Improving the efficacy and safety of adoptive cellular therapies
JP2025061674A (ja) 前立腺特異的膜抗原ｃａｒおよびその使用方法
AU2017268399B2 (en) mRNA combination therapy for the treatment of cancer
KR102779944B1 (ko) 키메라 수용체 및 그의 사용 방법
US11890301B2 (en) Methods and compositions for cells expressing a chimeric intracellular signaling molecule
KR102095700B1 (ko) 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
RU2139934C1 (ru) Гуманизированные антитела и их использование
US8715645B2 (en) Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
EA013677B1 (ru) Человеческие моноклональные антитела против cd25 и их применение
US11993659B2 (en) BCMA targetting antibodies, chimeric antigen receptors, and uses thereof
CN109475541A (zh) 用于治疗非erk mapk通路抑制剂抗性癌症的方法和组合物
US20020150559A1 (en) Induction of T cell tolerance with CD40/B7 antagonists
KR102804751B1 (ko) Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
PT96509A (pt) Anticorpos recombinantes humanos anti-cd18
KR20060022646A (ko) Ｓｔｏｐ-1 관련 조성물 및 방법
JP5198715B2 (ja) 物（ｓｕｂｓｔａｎｃｅｓ）
US11649435B2 (en) Methods and compositions for cells expressing a chimeric intracellular signaling molecule
WO2023019398A1 (en) Bcma targetting antibodies, chimeric antigen receptors, and uses thereof
CN115335396A (zh) 靶向cd33的嵌合抗原受体
KR20230002681A (ko) 대형 아데노바이러스 페이로드의 통합
HK1070079A (en) Antibodies specific for cd44v6
PT2190469E (pt) Polipéptidos e polinucleótidos, e utilizações dos mesmos como um alvo de fármacos para produzir fármacos e agentes biológicos
US11897966B2 (en) Mesothelin-targetting antibodies, chimeric antigen receptors, and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070079

Country of ref document: HK

AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070079

Country of ref document: HK